Pradefovir mesylate
CAS No. 625095-61-6
Pradefovir mesylate ( Remofovir mesylate | Hepavir B | Pradefovir mesilate )
产品货号. M27105 CAS No. 625095-61-6
甲磺酸普拉德福韦在人肝微粒体中转化为 9-(2-膦酰甲氧基乙基)腺嘌呤 (PMEA),Km 为 60 μM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥3012 | 有现货 |
|
| 10MG | ¥4323 | 有现货 |
|
| 25MG | ¥6398 | 有现货 |
|
| 50MG | ¥8807 | 有现货 |
|
| 100MG | ¥11430 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pradefovir mesylate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述甲磺酸普拉德福韦在人肝微粒体中转化为 9-(2-膦酰甲氧基乙基)腺嘌呤 (PMEA),Km 为 60 μM。
-
产品描述Pradefovir mesylate is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with Km of 60 μM.(In Vitro):Pradefovir was converted to PMEA in human liver microsomes with a Km of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min.?Addition of ketoconazole and monoclonal antibody 3A4 significantly inhibits the conversion of pradefovir to PMEA in human liver microsomes, suggesting the predominant role of CYP3A4 in the metabolic activation of pradefovir.?Pradefovir at 0.2, 2, and 20 microM was neither a direct inhibitor nor a mechanism-based inhibitor of CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 in human liver microsomes.(In Vivo):In rats, the liver was the site of metabolic activation of pradefovir, whereas the small intestine did not play a significant role in the metabolic conversion of pradefovir to PMEA.?Daily oral dosing (300 mg/kg) to rats for 8 days showed that pradefovir was not an inducer of P450 enzymes in rats.?
-
体外实验Pradefovir is a cyclodiester prodrug of PMEA. It is one of the Hep Direct prodrugs, which are designed to be efficiently and specifically activated through an oxidative reaction catalyzed by CYP3A4, which is located mainly in the liver.Pradefovir is converted to PMEA in human liver microsomes with a Km of 60 μM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 L/min.
-
体内实验Daily oral dosing of Pradefovir (300 mg/kg) to rats for 8 days does not affect body weight; liver weight; liver weight-body weight ratio; liver microsomal protein content; total CYP content; enzyme activities for CYP1A, CYP2B, and CYP3A; and apoprotein contents for CYP1A1, CYP2B1/2, CYP3A1/2, and CYP4A1/3, indicating that Pradefovir is not a CYP inducer in rats.
-
同义词Remofovir mesylate | Hepavir B | Pradefovir mesilate
-
通路Metabolic Enzyme/Protease
-
靶点P450
-
受体ACAT
-
研究领域——
-
适应症——
化学信息
-
CAS Number625095-61-6
-
分子量519.89
-
分子式C18H23ClN5O7PS
-
纯度>98% (HPLC)
-
溶解度In Vitro:?H2O : 100 mg/mL (192.34 mM)
-
SMILESCS(O)(=O)=O.Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.1. Adameová A, et al. The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. Eur J Pharmacol. 2007;576(1-3):114-121.
产品手册
关联产品
-
7-BFC
7-Benzyloxy-4-(trifluoromethyl)coumarin (7-BFC) 是一种香豆素荧光底物。7-Benzyloxy-4-(trifluoromethyl)coumarin 是 cDNA 表达的 CYP1A2 和 CYP3A4 的底物,代谢为 7-hydroxy-4-trifluoromethylcoumarin (HFC)。7-Benzyloxy-4-(trifluoromethyl)coumarin 用于快速 CYP 亚型代谢和抑制筛选研究。
-
Cholesterol 24-hydro...
Cholesterol 24-hydroxylase-IN-1 (compound 17) 是一种强效、口服活性和高选择性的胆固醇24-羟化酶 (CH24H or CYP46A1) 抑制剂 (IC50=8.5 nM)。Cholesterol 24-hydroxylase-IN-1 能透过血脑屏障。
-
Gnetol
Gnetol 竞争性抑制丁酰胆碱酯酶 (IC50: 1.3 uM)。 Gnetol 对小鼠酪氨酸酶活性有很强的抑制作用。
021-51111890
购物车()
sales@molnova.cn

